Cabozantinib
A multikinase inhibitor that blocks several receptors including VEGFR, MET, and RET involved in tumor growth and spread. It is used to treat advanced renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer. Side effects include hypertension, diarrhea, hand-foot skin reaction, and liver function abnormalities.
Peso Molecular
501,5000 g/mol
LogP
5,40
TPSA
98,80 Ų
Regra dos 5 de Lipinski
Reprovado
Áreas Terapêuticas
Mecanismo de Ação
Inhibits vascular endothelial growth factor (VEGF) signaling, blocking angiogenesis (new blood vessel formation) that tumors require for growth and metastasis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits vascular endothelial growth factor (VEGF) signaling, blocking angiogenesis (new blood vessel formation) that tumors require for growth and metastasis.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC
InChI
InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)
Molecular Formula
C28H24FN3O5
HBD / HBA
2 / 7
Ligações Rotacionáveis
8
Átomos Pesados
37
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
A multikinase inhibitor that blocks several receptors including VEGFR, MET, and RET involved in tumor growth and spread. It is used to treat advanced renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer. Side effects include hypertension, diarrhea, hand-foot skin reaction, and liver function abnormalities.
Inhibits vascular endothelial growth factor (VEGF) signaling, blocking angiogenesis (new blood vessel formation) that tumors require for growth and metastasis.
Yes, Cabozantinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2105717. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 25102847. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="cabozantinib"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/cabozantinib/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/cabozantinib/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/cabozantinib/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="cabozantinib"></drugfyi-drug>